|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM096590122 |
003 |
DE-627 |
005 |
20231222104152.0 |
007 |
tu |
008 |
231222s1998 xx ||||| 00| ||jpn c |
028 |
5 |
2 |
|a pubmed24n0322.xml
|
035 |
|
|
|a (DE-627)NLM096590122
|
035 |
|
|
|a (NLM)9719946
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a jpn
|
100 |
1 |
|
|a Ishihara, S
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Fleroxacin treatment for acute uncomplicated cystitis in women
|b comparison of 3-day and 7-day therapy
|
264 |
|
1 |
|c 1998
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 15.09.1998
|
500 |
|
|
|a Date Revised 21.11.2013
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a The clinical efficacy of fleroxacin (FLRX), a new fluoroquinolone, for acute uncomplicated cystitis (AUC) in women was assessed. Two regimens, 3-day and 7-day courses of FLRX, 200 mg once a day, were compared. Clinical and bacteriological efficacy were evaluated after the therapy, and recurrence rate was evaluated 1 week and 4 weeks after termination of the therapy. Of 136 registered subjects, 35 in the 3-day group and 47 in the 7-day group were evaluated. According to the criteria of Japanese UTI Committee (3rd edition), the rate of excellent results was significantly higher in the 7-day group (78.9%) than in the 3-day group (48.6%), but the overall clinical efficacy rate was similar being 100% and 97.9%, respectively. Although no recurrence was seen 1 week after the therapy in either group, recurrence was seen in 14.3% and 7.4% of the cases in the 3-day and 7-day groups, respectively, 4 weeks after the therapy. Adverse reactions were observed in 2 and 3 cases in the 3-day and 7-day groups, respectively. Both 3-day and 7-day regimens of FLRX treatment showed good efficacy. Although the 7-day treatment was superior to the 3-day treatment as to high rate of excellent results and low rate of recurrence, the 3-day treatment was concluded to be sufficient for AUC
|
650 |
|
4 |
|a Clinical Trial
|
650 |
|
4 |
|a Comparative Study
|
650 |
|
4 |
|a English Abstract
|
650 |
|
4 |
|a Journal Article
|
650 |
|
7 |
|a Anti-Infective Agents
|2 NLM
|
650 |
|
7 |
|a Fleroxacin
|2 NLM
|
650 |
|
7 |
|a N804LDH51K
|2 NLM
|
700 |
1 |
|
|a Ban, Y
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kawada, Y
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ito, S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ito, Y
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Doi, T
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Nezasa, S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fujihiro, S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Yamaha, M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ito, F
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Iwata, H
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Hasegawa, Y
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ueno, K
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shinoda, I
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Taniguchi, M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Minoshima, K
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Takeuchi, T
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sakai, S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Uno, H
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Koide, T
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 44(1998), 6 vom: 14. Juni, Seite 431-6
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
773 |
1 |
8 |
|g volume:44
|g year:1998
|g number:6
|g day:14
|g month:06
|g pages:431-6
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_20
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_120
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2018
|
951 |
|
|
|a AR
|
952 |
|
|
|d 44
|j 1998
|e 6
|b 14
|c 06
|h 431-6
|